| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.02 | -0.01 (-0.49%) | 1.70 - 5.63 | 123.4 thousand (Below Avg) |
Market data as of 3:59PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 2.02 |
|---|---|
| Previous Close | 2.03 |
| Day's Range | 1.98 - 2.04 |
| Market Cap | 51.2M |
| Avg Volume (10 Day) | 216.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.33 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting
PR Newswire - Thursday 05/23/2013 7:30 AM ET
Aeterna Zentaris Announces "At-the-Market" Issuance Program
PR Newswire - Tuesday 05/21/2013 4:53 PM ET
Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders
PR Newswire - Wednesday 05/08/2013 4:05 PM ET
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results
PR Newswire - Tuesday 05/07/2013 4:44 PM ET
Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013
PR Newswire - Wednesday 05/01/2013 7:30 AM ET
| AEZS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 6.76% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 1.26 |
| Company | Last | Change |
|---|---|---|
| Affymax Inc | 1.39 | -0.71% |
| Celsion Corp | 1.04 | +5.05% |
| EntreMed Inc | 1.77 | -0.56% |
| Transcept Pharmaceuticals Inc | 3.10 | +0.65% |
| Rexahn Pharmaceuticals Inc | 0.36 | -6.95% |
Data is delayed by at least 15 min.